Boryung Pharmaceutical Acquires Domestic Rights for US Lilly's Schizophrenia Treatment for 37.6 Billion KRW
[Asia Economy Reporter Ji Yeon-jin] Boryung Pharmaceutical announced on the 21st that it has acquired the domestic distribution rights for the schizophrenia treatment drug Zyprexa from the US pharmaceutical company Lilly for $32 million (KRW 37.6 billion). The contract period starts from today with no expiration.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "To Get Revenge on Ex-Girlfriend" US McDonald's Manager Spits on French Fries
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
The company explained that Zyprexa, launched in 1996, is the most prescribed schizophrenia treatment drug worldwide, and it continues to hold the number one prescription amount domestically with over 50% market share in the olanzapine market (KRW 14 billion in sales as of last year).
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
